Literature DB >> 8493578

Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.

C Y Wang1, B Petryniak, C B Thompson, W G Kaelin, J M Leiden.   

Abstract

The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8493578     DOI: 10.1126/science.8493578

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  58 in total

1.  Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins.

Authors:  F A Dick; E Sailhamer; N J Dyson
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

5.  Dynamics of a simple regulatory switch.

Authors:  Erik Boczko; Tomás Gedeon; Konstantin Mischaikow
Journal:  J Math Biol       Date:  2007-07-11       Impact factor: 2.259

Review 6.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

7.  The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein.

Authors:  I M Buyse; G Shao; S Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.

Authors:  Yan Liu; Cyrus V Hedvat; Shifeng Mao; Xin-Hua Zhu; Jinjuan Yao; Hoang Nguyen; Andrew Koff; Stephen D Nimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

Authors:  M W Chang; E Barr; M M Lu; K Barton; J M Leiden
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.